| Chitinase-3-like 1 protein complexes modulate macrophage-mediated immune suppression in glioblastoma A Chen, Y Jiang, Z Li, L Wu, U Santiago, H Zou, C Cai, V Sharma, Y Guan, ... The Journal of clinical investigation 131 (16), 2021 | 78 | 2021 |
| Natural coevolution of tumor and immunoenvironment in glioblastoma L Wu, W Wu, J Zhang, Z Zhao, L Li, M Zhu, M Wu, F Wu, F Zhou, Y Du, ... Cancer discovery 12 (12), 2820-2837, 2022 | 58 | 2022 |
| Molecular features of pleomorphic xanthoastrocytoma H Zou, Y Duan, D Wei, Y Zhang, J Dai, J Li, X Li, J Zhou, Z Liu, Z Jin, ... Human Pathology 86, 38-48, 2019 | 28 | 2019 |
| Molecular heterogeneity and cellular diversity: implications for precision treatment in medulloblastoma H Zou, B Poore, A Broniscer, IF Pollack, B Hu Cancers 12 (3), 643, 2020 | 23 | 2020 |
| Alterations in 3D chromatin organization contribute to tumorigenesis of EGFR-amplified glioblastoma Q Yang, N Jiang, H Zou, X Fan, T Liu, X Huang, S Wanggou, X Li Computational and Structural Biotechnology Journal 20, 1967-1978, 2022 | 15 | 2022 |
| A neurodevelopmental epigenetic programme mediated by SMARCD3–DAB1–Reelin signalling is hijacked to promote medulloblastoma metastasis H Zou, B Poore, EE Brown, J Qian, B Xie, E Asimakidou, V Razskazovskiy, ... Nature cell biology 25 (3), 493-507, 2023 | 13 | 2023 |
| Construction and validation of a 13-gene signature for prognosis prediction in medulloblastoma C Li, H Zou, Z Xiong, Y Xiong, DF Miyagishima, S Wanggou, X Li Frontiers in Genetics 11, 429, 2020 | 8 | 2020 |
| Tumor niches: perspectives for targeted therapies in glioblastoma R Srivastava, M Dodda, H Zou, X Li, B Hu Antioxidants & Redox Signaling 39 (13-15), 904-922, 2023 | 7 | 2023 |
| Development of a human glioblastoma model using humanized DRAG mice for immunotherapy R Srivastava, A Labani-Motlagh, A Chen, JA Bohorquez, B Qin, M Dodda, ... Antibody Therapeutics 6 (4), 253-264, 2023 | 7 | 2023 |
| Survival risk prediction models of gliomas based on IDH and 1p/19q H Zou, C Li, S Wanggou, X Li Journal of Cancer 11 (15), 4297, 2020 | 5 | 2020 |
| Protocol to assess the antitumor efficacy of an immunotherapeutic peptide in syngeneic orthotopic glioma mouse models A Chen, Y Chao, H Zou, LH McCarl, G Kohanbash, B Hu STAR protocols 4 (1), 102049, 2023 | 4 | 2023 |
| Assessment of anti-CD69 antibody therapy alone or in combination with anti-PD-1 in murine GBM M Nisnboym, CT Sneiderman, AP Jaswal, Z Xiong, SR Vincze, RAE Sever, ... Expert Review of Clinical Immunology, 1-9, 2024 | | 2024 |
| CNSC-34. BAF60C/SMARCD3 MODULATES CEREBELLUM DEVELOPMENT AND MEDULLOBLASTOMA METASTASIS H Zou, Y Patel, C Sneiderman, A Talluru, A Zheng, T Pearce, S Agnihotri, ... Neuro-Oncology 25 (Supplement_5), v30-v30, 2023 | | 2023 |
| TMIC-49. CHITINASE-3-LIKE 1 PROTEIN COMPLEXES REGULATE PD-1 SIGNALING-MEDIATED IMMUNOSUPPRESSION IN GLIOBLASTOMA R Srivastava, A Chen, M Dodda, H Zou, B Hu Neuro-Oncology 24 (Supplement_7), vii282-vii282, 2022 | | 2022 |
| EXTH-79. HIJACKING A NEURODEVELOPMENTAL EPIGENOMIC PROGRAM IN METASTATIC DISSEMINATION OF MEDULLOBLASTOMA H Zou, B Poore, E Brown, P Yash, Z Hu, X Li, IF Pollack, RM Friedlander, ... Neuro-Oncology 24 (Supplement_7), vii227-vii227, 2022 | | 2022 |
| MEDB-88. BAF60C/SMARCD3-mediated novel neurodevelopmental epigenomic program promotes metastatic dissemination in medulloblastoma H Zou, B Poore, E Brown, Z Hu, X Li, I Pollack, R Friedlander, S Hainer, ... Neuro-Oncology 24 (Supplement_1), i127-i127, 2022 | | 2022 |
| MBRS-63. THE ROLE OF THE SWI/SNF COMPLEX SUBUNIT SMARCD3 IN MEDULLOBLASTOMA B Poore, H Zou, V Sharma, I Pollack, B Hu Neuro-Oncology 22 (Suppl 3), iii409, 2020 | | 2020 |
| Survival Risk Prediction Models of Glioma Based on IDH and 1p/19q H Zou, S Wanggou, X Li Journal of Cancer 10 (23), 5832-5842, 2019 | | 2019 |
